Canary Fund
- Assets
- $1.7m
- Revenue
- $1.9m
- Investments
- $0.0
- Employees
- 3
- Location
- Woodside, CA
- Founding
- 06/2005
- Data as of
- 12/2023
- EIN
- 65-1230251
Organization Overview
Canary Fund is located in Woodside, CA. The organization was established in 2005. According to its NTEE Classification (T30) the organization is classified as: Public Foundations, under the broad grouping of Philanthropy, Voluntarism & Grantmaking Foundations and related organizations. As of 12/2023, Canary Fund employed 3 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Canary Fund is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2023, Canary Fund generated $1.9m in total revenue. This represents a relatively dramatic decline in revenue. Over the past 9 years, the organization has seen revenues fall by an average of (6.1%) each year. All expenses for the organization totaled $1.4m during the year ending 12/2023. As we would expect to see with falling revenues, expenses have declined by (16.6%) per year over the past 9 years. You can explore the organizations financials more deeply in the financial statements section below.
Since 2015, Canary Fund has awarded 71 individual grants totaling $13,575,042. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2023
Describe the Organization's Mission:
Part 3 - Line 1
CANARY FOUNDATION IS THE WORLD'S FIRST NON-PROFIT ORGANIZATION DEDICATED SOLELY TO THE FUNDING, DISCOVERY AND DEVELOPMENT OF TESTS FOR EARLY CANCER DETECTION.
Describe the Organization's Program Activity:
Part 3 - Line 4a
THE GOAL OF THE CANARY SCIENTIFIC PROGRAMS IS TO DEVELOP BLOOD TESTS AND IMAGING TESTS THAT CAN TOGETHER BE USED TO DETECT LETHAL CANCERS AT A CURABLE STAGE. OUR PLAN FOR EARLY AND ACCURATE CANCER DETECTION INVOLVES FIRST SCREENING PATIENTS WITH A BLOOD TEST AND THEN MOVING THOSE PATIENTS WHO TESTED POSITIVE TO A HIGH-RESOLUTION IMAGING TEST TO FURTHER ISOLATE CANCER SO THAT IT CAN BE REMOVED. CANARY FOUNDATION IS FOCUSED ON FIVE CANCER TYPES, EACH OF WHICH PRESENTS A SIGNIFICANT OPPORTUNITY TO SAVE LIVES AND PREVENT UNNECESSARY TREATMENTS THROUGH EARLY DETECTION OF OTHERWISE LETHAL DISEASE: CANCER OF THE OVARY, PANCREAS, LUNG, BREAST AND PROSTATE. CHANCES OF SURVIVAL ARE HIGHEST WHEN CANCER IS DETECTED BEFORE IT SPREADS. THUS, ACCURATE DETECTION OF CANCER THAT WOULD OTHERWISE BE LETHAL AT ITS EARLIEST STAGE PROMISES TO DRAMATICALLY IMPROVE SURVIVAL AFTER DIAGNOSIS. CANARY SUPPORTS EARLY DETECTION
RESEARCH PROGRAMS IN EACH OF THESE CANCER AREAS AS WELL AS A COLLABORATIONS PROGRAM WITH COLLABORATING EARLY DETECTION PROGRAMS AND CENTERS THAT INCLUDE THE CANARY CENTER AT STANFORD FOR CANCER EARLY DETECTION.CANARY OVARIAN CANCER PROGRAM: THE GOAL OF OUR OVARIAN RESEARCH PROGRAM IS TO DEVELOP A STRATEGY TO ACCURATELY IDENTIFY OVARIAN CANCERS THAT WOULD OTHERWISE BE LETHAL AT A STAGE WHEN THEY ARE READILY CURABLE. OUR VISION IS OF A TWO-STAGE SCREENING STRATEGY, CONSISTING OF A SIMPLE BLOOD TEST FOLLOWED BY A MOLECULAR IMAGING TEST. DEVELOPMENT OF BLOOD AND IMAGING TESTS FOLLOWS A SIMILAR ROADMAP; BOTH INCLUDE BIOMARKER DISCOVERY FOLLOWED BY VALIDATION, BUT THEY ALSO INVOLVE DIFFERENT TECHNIQUES AND CHALLENGES.
CANARY LUNG CANCER PROGRAM:CANARY IS FOCUSED ON DEVELOPING DIAGNOSTICS WITH HIGH SENSITIVITY AND SPECIFICITY TO DETECT OTHERWISE LETHAL LUNG CANCERS AT A STAGE WHEN THEY ARE READILY CURABLE. TO THIS END, CANARY HAS ASSEMBLED A TEAM OF EXPERTS WHO ARE COLLABORATING TO DISCOVER AND VALIDATE BIOMARKERS FOR BLOOD AND IMAGING TESTS THAT TOGETHER WILL IDENTIFY INDIVIDUALS HARBORING LETHAL LUNG CANCERS SO THAT THEY CAN BE REMOVED.THE CANARY LUNG CANCER PROGRAM HAS SUPPORTED THE DEVELOPMENT AND MAINTENANCE OF CRITICAL BIOSPECIMEN RESOURCES, BLOOD BIOMARKER DISCOVERY AND VALIDATION, MOLECULAR IMAGING PROJECTS FOR EARLY DETECTION OF LETHAL LUNG CANCER, AND EPIDEMIOLOGY AND MODELING FOR EFFECTIVE LUNG CANCER SCREENING. (CONTINUED ON SCHEDULE O)
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Heidi Auman Program Manager | 40 | $168,000 | |
Don Listwin Founder & CEO | OfficerTrustee | 8 | $0 |
Kevin Kennedy Treasurer | OfficerTrustee | 4 | $0 |
Michael Ball Director | Trustee | 4 | $0 |
Dale Jantzen Director | Trustee | 4 | $0 |
Hilary Valentine Director | Trustee | 4 | $0 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $1,858,743 |
| Noncash contributions included in lines 1a–1f | $96,738 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $1,858,743 |
| Total Program Service Revenue | $0 |
| Investment income | $24,569 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $0 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $1,883,312 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $854,570 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $26,470 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $0 |
| Compensation of current officers, directors, key employees. | $0 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $152,806 |
| Pension plan accruals and contributions | $22,500 |
| Other employee benefits | $0 |
| Payroll taxes | $70,388 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $0 |
| Fees for services: Accounting | $3,416 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $0 |
| Fees for services: Other | $19,301 |
| Advertising and promotion | $0 |
| Office expenses | $536 |
| Information technology | $186 |
| Royalties | $0 |
| Occupancy | $0 |
| Travel | $25,374 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $0 |
| Interest | $250 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $11,139 |
| Insurance | $4,054 |
| All other expenses | $1,932 |
| Total functional expenses | $1,352,591 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $292,799 |
| Savings and temporary cash investments | $760,329 |
| Pledges and grants receivable | $468,333 |
| Accounts receivable, net | $0 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $0 |
| Net Land, buildings, and equipment | $46,265 |
| Investments—publicly traded securities | $0 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $120,192 |
| Total assets | $1,687,918 |
| Accounts payable and accrued expenses | $23,683 |
| Grants payable | $0 |
| Deferred revenue | $0 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $0 |
| Total liabilities | $23,683 |
| Net assets without donor restrictions | $1,085,709 |
| Net assets with donor restrictions | $578,526 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $1,687,918 |
Grants Awarded
Over the last fiscal year, Canary Fund has awarded $854,570 in support to 9 organizations.
| Grant Recipient | Amount |
|---|---|
SEATTLE INST BIOMEDICAL CLINICAL PURPOSE: Cancer Research | $29,600 |
BETH ISRAEL DEACONESS MEDICAL PURPOSE: Cancer Research | $40,000 |
STANFORD SCHOOL OF MEDICINE PURPOSE: Cancer Research | $106,120 |
UNIVERSITY OF MICHIGAN PURPOSE: Cancer Research | $18,000 |
UNIV OF CALIF - SAN FRANCISCO PURPOSE: Cancer Research | $20,000 |
STANFORD UNIVERSITY PURPOSE: Cancer Research | $13,650 |